Neuronal nicotinic acetylcholine receptors - Targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease

Current Topics in Medicinal Chemistry

Volumn 10, Issue 2, 2010, Pages 144-152

  Haydar, Simon N ^a   Dunlop, John ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; A 582941; A 582951; A 867744; ARR 17779; AZD 0328; EVP 6124; ISPRONICLINE; JN 403; MEM 3454; N (1 AZABICYCLO[3.2.1]OCT 3 YL)FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4; NICOTINIC RECEPTOR BETA2; NS 1738; PARTIAL AGONIST; PH 399733; PH 543513; PH 568487; PNU 120596; S 24795; SEN 12333; TC 2559; TC 5619; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 264620; WAY 317538; XY 4083;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; PARTIAL AGONISM; REVIEW; SCHIZOPHRENIA;

ALZHEIMER DISEASE; COGNITION DISORDERS; DRUG DISCOVERY; NICOTINIC ANTAGONISTS; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949422530     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610790410983     Document Type: Review

References (72)

1. Lindstrom, J. Neuronal nicotinic acetylcholine receptors. Ion Channels, (N. Y.) 1996, 4, 377-450.
2. Lindstrom, J.; Anand, R.; Gerzanich, V.; Peng, X.; Wang, F.; Wells, G. Structure and function of neuronal nicotinic acetylcholine receptors. Prog. Brain Res., 1996, 109, 125-137.
3. Gotti, C.; Clementi, F. Neuronal nicotinic receptors: from structure to pathology. Prog. Neurobiol., (Amsterdam, Neth.) 2004, 74, 363-396.
4. Gotti, C.; Riganti, L.; Vailati, S.; Clementi, F. Brain neuronal nicotinic receptors as new targets for drug discovery. Curr. Pharm. Des., 2006, 12, 407-428.
5. Jones, H. E.; Garrett, B. E.; Griffiths, R. R. Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers. J. Pharmacol. Exp. Ther., 1999, 288, 188-197.
6. Buccafusco, J. J.; Jackson, W. J. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol. Aging, 1991, 12, 233-238.
7. Westman, E. C.; Levin, E. D.; Rose, J. E. Nicotine as a therapeutic drug. N. C. Med. J., 1995, 56, 48-51.
8. Woodruff-Pak, D. S.; Santos, I. S. Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease. Behav. Brain Res., 2000, 113, 11-19.
9. White, H. K.; Levin, E. D. Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology (Berlin, Ger.), 2004, 171, 465-471.
10. Hoyle, E.; Genn, R. F.; Fernandes, C.; Stolerman, I. P. Impaired performance of alpha 7 nicotinic receptor knockout mice in the five-choice serial reaction time task. Psychopharmacology (Berlin, Ger.) 2006, 189, 211-223.
11. Spinelli, S.; Ballard, T.; Feldon, J.; Higgins, G. A.; Pryce, C. R. Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys. Neuropharmacology, 2006, 51, 238-250.
12. Freedman, R.; Hall, M.; Adler, L. E.; Leonard, S., Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry, 1995, 38, 22-33.
13. Qi, X.-L.; Nordberg, A.; Xiu, J.; Guan, Z.-Z. The consequences of reducing expression of the alpha 7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha 7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. Neurochem. Int., 2007, 51, 377-383.
14. Freedman, R.; Leonard, S.; Olincy, A.; Kaufmann, C. A.; Malaspina, D.; Cloninger, C. R.; Svrakic, D.; Faraone, S. V.; Tsuang, M. T. Evidence for the multigenic inheritance of schizophrenia. Am. J. Med. Genet., 2001, 105, 794-800.
15. Freedman, R.; Leonard, S. Genetic linkage to schizophrenia at chromosome 15q14. Am. J. Med. Genet., 2001, 105, 655-657.
16. Woodruff-Pak Diana, S. Mecamylamine reversal by nicotine and by a partial alpha7 nicotinic acetylcholine receptor agonist (GTS-21) in rabbits tested with delay eyeblink classical conditioning. Behav. Brain Res., 2003, 143, 159-167.
17. Meyer, E. M.; Tay, E. T.; Papke, R. L.; Meyers, C.; Huang, G.-l.; de Fiebre, C. M. 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha 7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res., 1997, 768, 49-56.
18. Briggs, C. A.; Anderson, D. J.; Brioni, J. D.; Buccafusco, J. J.; Buckley, M. J.; Campbell, J. E.; Decker, M. W.; Donnelly-Roberts, D.; Elliott, R. L.; Gopalakrishnan, M.; Holladay, M. W.; Hui, Y.-H.; Jackson, W. J.; Kim, D. J. B.; Marsh, K. C.; O'Neill, A.; Prendergast, M. A.; Ryther, K. B.; Sullivan, J. P.; Arneric, S. P. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol., Biochem. Behav., 1997, 57, 231-241.
19. Arendash, G. W.; Sengstock, G. J.; Sanberg, P. R.; Kem, W. R. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res., 1995, 674, 252-259.
20. Levin, E. D.; Bettegowda, C.; Blosser, J.; Gordon, J. AR-R17779, an alpha7 nicotinic agonist, improves learning and memory in rats. Behav. Pharmacol., 1999, 10, 675-680.
21. Mullen, G.; Napier, J.; Balestra, M.; DeCory, T.; Hale, G.; Macor, J.; Mack, R.; Loch, J., III; Wu, E.; Kover, A.; Verhoest, P.; Sampognaro, A.; Phillips, E.; Zhu, Y.; Murray, R.; Griffith, R.; Blosser, J.; Gurley, D.; Machulskis, A.; Zongrone, J.; Rosen, A.; Gordon, J. (-)-Spiro[1-azabicyclo[2.2. 2]octane-3,5′-oxazolidin-2′-one], a conformationally restricted analog of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. J. Med. Chem., 2000, 43, 4045-4050.
22. van Kampen, M.; Selbach, K.; Schneider, R.; Schiegel, E.; Boess, F.; Schreiber, R. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha 7 receptors. Psychopharmacology (Berlin, Ger.), 2004, 172, 375-383.
23. Biton, B.; Bergis, O. E.; Galli, F.; Nedelec, A.; Lochead, A. W.; Jegham, S.; Godet, D.; Lanneau, C.; Santamaria, R.; Chesney, F.; Leonardon, J.; Granger, P.; Debono, M. W.; Bohme, G. A.; Sgard, F.; Besnard, F.; Graham, D.; Coste, A.; Oblin, A.; Curet, O.; Vige, X.; Voltz, C.; Rouquier, L.; Souilhac, J.; Santucci, V.; Gueudet, C.; Francon, D.; Steinberg, R.; Griebel, G.; Oury-Donat, F.; George, P.; Avenet, P.; Scatton, B. SSR180711, a novel selective alpha 7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology, 2007, 32, 1-16.
24. Pichat, P.; Bergis Olivier, E.; Terranova, J.-P.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C.; Steinberg, R.; Stemmelin, J.; Oury-Donat, F.; Avenet, P.; Griebel, G.; Scatton, B. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology., 2007, 32, 17-34.
25. Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol. Psychiatry, 2008, 63, 92-97.
26. Hajos, M.; Hurst, R. S.; Hoffmann, W. E.; Krause, M.; Wall, T. M.; Higdon, N. R.; Groppi, V. E. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo [2.2.2]oct-3-yl]-4- chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J. Pharmacol. Exp. Ther., 2005, 312, 1213-1222.
27. Tietje, K. R.; Anderson, D. J.; Bitner, R. S.; Blomme, E. A.; Brackemeyer, P. J.; Briggs, C. A.; Browman, K. E.; Bury, D.; Curzon, P.; Drescher, K. U.; Frost, J. M.; Fryer, R. M.; Fox, G. B.; Gronlien, J. H.; Hakerud, M.; Gubbins, E. J.; Halm, S.; Harris, R.; Helfrich, R. J.; Kohlhaas, K. L.; Law, D.; Malysz, J.; Marsh, K. C.; Martin, R. L.; Meyer, M. D.; Molesky, A. L.; Nikkel, A. L.; Otte, S.; Pan, L.; Puttfarcken, P. S.; Radek, R. J.; Robb, H. M.; Spies, E.; Thorin-Hagene, K.; Waring, J. F.; Ween, H.; Xu, H.; Gopalakrishnan, M.; Bunnelle, W. H. Preclinical characterization of A-582941: a novel alpha 7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci. Ther., 2008, 14, 65-82.
28. Buccafusco Jerry, J.; Terry Alvin, V., Jr.; Decker Michael, W.; Gopalakrishnan, M. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem. Pharmacol., 2007, 74, 1202-1211.
29. Feuerbach, D.; Nozulak, J.; Lingenhoehl, K.; McAllister, K.; Hoyer, D. JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha 7 selective agonist. Neurosci. Lett., 2007, 416, 61-65.
30. Boess Frank, G.; De Vry, J.; Erb, C.; Flessner, T.; Hendrix, M.; Luithle, J.; Methfessel, C.; Riedl, B.; Schnizler, K.; van der Staay, F.-J.; van Kampen, M.; Wiese Welf, B.; Koenig, G. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1- benzofuran-2-carboxamide improves working and recognition memory in rodents. J. Pharmacol. Exp. Ther., 2007, 321, 716-725.
31. Lopez-Hernandez, G.; Placzek Andon, N.; Thinschmidt Jeffrey, S.; Lestage, P.; Trocme-Thibierge, C.; Morain, P.; Papke Roger, L. Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons. Neuropharmacology, 2007, 53, 134-144.
32. Lagostena, L.; Trocme-Thibierge, C.; Morain, P.; Cherubini, E. The partial alpha7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus. Neuropharmacology, 2008, 54, 676-685.
33. Marighetto, A.; Valerio, S.; Desmedt, A.; Philippin, J. N.; Trocme-Thibierge, C.; Morain, P. Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. Psychopharmacology (Berl.), 2008, 197, 499-508.
34. Acker, B. A.; Jacobsen, E. J.; Rogers, B. N.; Wishka, D. G.; Reitz, S. C.; Piotrowski, D. W.; Myers, J. K.; Wolfe, M. L.; Groppi, V. E.; Thornburgh, B. A.; Tinholt, P. M.; Walters, R. R.; Olson, B. A.; Fitzgerald, L.; Staton, B. A.; Raub, T. J.; Krause, M.; Li, K. S.; Hoffmann, W. E.; Hajos, M.; Hurst, R. S.; Walker, D. P. Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3- c]pyridine-5-carboxamide as an agonist of the alpha 7 nicotinic acetylcholine receptor: In vitro and in vivo activity. Bioorg. Med. Chem. Lett., 2008, 18, 3611-3615.
35. Rezvani Amir, H.; Kholdebarin, E.; Brucato Frederic, H.; Callahan Patrick, M.; Lowe David, A.; Levin Edward, D. Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33, 269-275.
36. Roncarati, R.; Scali, C.; Comery Thomas, A.; Grauer Steven, M.; Aschmi, S.; Bothmann, H.; Jow, B.; Kowal, D.; Gianfriddo, M.; Kelley, C.; Zanelli, U.; Ghiron, C.; Haydar, S.; Dunlop, J.; Terstappen Georg, C. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J. Pharmacol. Exp. Ther., 2009, 329, 459-468.
37. Obinu, M. C.; Reibaud, M.; Miquet, J. M.; Pasquet, M.; Rooney, T. Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 2002, 26, 913-918.
38. Gatto, G. J.; Bohme, G. A.; Caldwell, W. S.; Letchworth, S. R.; Traina, V. M.; Obinu, M. C.; Laville, M.; Reibaud, M.; Pradier, L.; Dunbar, G.; Bencherif, M. TC-1734: An orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev., 2004, 10, 147-166.
39. Dunbar, G.; Boeijinga, P. H.; Demazieres, A.; Cisterni, C.; Kuchibhatla, R.; Wesnes, K.; Luthringer, R. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berlin, Ger.), 2007, 191, 919-929.
40. Dunbar, G.; Demazieres, A.; Monreal, A.; Cisterni, C.; Metzger, D.; Kuchibhatla, R.; Luthringer, R., Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers. J. Clin. Pharmacol., 2006, 46, 715-726.
41. Schreiber, R.; Dalmus, M.; De Vry, J., Effects of alpha 4/beta 2-and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology (Berl), 2002, 159, 248-257.
42. Bencherif, M.; Bane, A. J.; Miller, C. H.; Dull, G. M.; Gatto, G. J. TC-2559: A novel orally active ligand selective at neuronal acetylcholine receptors. Eur. J. Pharmacol., 2000, 409, 45-55.
43. Lippiello, P.; Letchworth, S. R.; Gatto, G. J.; Traina, V. M.; Bencherif, M. Ispronicline: a novel alpha 4beta 2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. J. Mol. Neurosci., 2006, 30, 19-20.
44. Hurst Raymond, S.; Hajos, M.; Raggenbass, M.; Wall Theron, M.; Higdon Nicole, R.; Lawson Judy, A.; Rutherford-Root Karen, L.; Berkenpas Mitchell, B.; Hoffmann, W. E.; Piotrowski David, W.; Groppi Vincent, E.; Allaman, G.; Ogier, R.; Bertrand, S.; Bertrand, D.; Arneric Stephen, P. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J. Neurosci., 2005, 25, 4396-4405.
45. Timmermann Daniel, B.; Gronlien Jens, H.; Kohlhaas Kathy, L.; Nielsen Elsebet, O.; Dam, E.; Jorgensen Tino, D.; Ahring Philip, K.; Peters, D.; Holst, D.; Chrsitensen Jeppe, K.; Malysz, J.; Briggs Clark, A.; Gopalakrishnan, M.; Olsen Gunnar, M. An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J. Pharmacol. Exp. Ther., 2007, 323, 294-307.
46. Ng Herman, J.; Whittemore Edward, R.; Tran Minhtam, B.; Hogenkamp Derk, J.; Broide Ron, S.; Johnstone Timothy, B.; Zheng, L.; Stevens Karen, E.; Gee Kelvin, W. Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc. Natl. Acad. Sci. USA, 2007, 104, 8059-8064.
47. Gronlien Jens, H.; Hakerud, M.; Ween, H.; Thorin-Hagene, K.; Briggs Clark, A.; Gopalakrishnan, M.; Malysz, J. Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol. Pharmacol.,2007, 72, 715-724.
48. Dunlop, J.; Lock, T.; Jow, B.; Sitzia, F.; Grauer, S.; Jow, F.; Kramer, A.; Bowlby Mark, R.; Randall, A.; Kowal, D.; Gilbert, A.; Comery Thomas, A.; Larocque, J.; Soloveva, V.; Brown, J.; Roncarati, R. Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b′]di pyrrole-1(2H)-carboxamide). J. Pharmacol. Exp. Ther., 2009, 328, 766-776.
49. Malysz, J.; Gronlien Jens, H.; Anderson David, J.; Hakerud, M.; Thorin-Hagene, K.; Ween, H.; Wetterstrand, C.; Briggs Clark, A.; Faghih, R.; Bunnelle William, H.; Gopalakrishnan, M. In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1- yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile. J. Pharmacol. Exp. Ther., 2009, 330, 257-267.
50. Bertrand, D.; Gopalakrishnan, M. Allosteric modulation of nicotinic acetylcholine receptors. Biochem. Pharmacol., 2007, 74, 1155-1163.
51. Lightfoot, A. P.; Kew, J. N. C.; Skidmore, J. Alpha 7 nicotinic acetylcholine receptor agonists and positive allosteric modulators. Prog. Med. Chem., 2008, 46, 131-171.
52. Romanelli, M. N.; Gualtieri, F. The quest for the treatment of cognitive impairment: alpha 7 nicotinic and alpha 5 GABAA receptor modulators. Expert Opin. Ther. Pat., 2007, 17, 1365-1377.
53. Mazurov, A.; Hauser, T.; Miller, C. H. Selective alpha 7 nicotinic acetylcholine receptor ligands. Curr. Med. Chem., 2007, 14, 1593.
54. Martin Laura, F.; Freedman, R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int. Rev. Neurobiol., 2007, 78, 225-246.
55. Kitagawa, H.; Takenouchi, T.; Azuma, R.; Wesnes, K. A.; Kramer, W. G.; Clody, D. E.; Burnett, A. L. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology, 2003, 28, 542-551.
56. Olincy, A.; Harris Josette, G.; Johnson Lynn, L.; Pender, V.; Kongs, S.; Allensworth, D.; Ellis, J.; Zerbe Gary, O.; Leonard, S.; Stevens Karen, E.; Stevens James, O.; Martin, L.; Adler Lawrence, E.; Soti, F.; Kem William, R.; Freedman, R. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry, 2006, 63, 630-638.
57. Freedman, R.; Olincy, A.; Buchanan Robert, W.; Harris Josette, G.; Gold James, M.; Johnson, L.; Allensworth, D.; Guzman-Bonilla, A.; Clement, B.; Ball, M. P.; Kutnick, J.; Pender, V.; Martin Laura, F.; Stevens Karen, E.; Wagner Brandie, D.; Zerbe Gary, O.; Soti, F.; Kem William, R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry, 2008, 165, 1040-1047.
58. Hauser, T. A.; Kucinski, A.; Jordan, K. G.; Gatto, G. J.; Wersinger, S. R.; Hesse, R. A.; Stachowiak, E. K.; Stachowiak, M. K.; Papke, R. L.; Lippiello, P. M.; Bencherif, M. TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem. Pharmacol., 2009, 78, 803-812.
59. Yohannes, D.; Mazurov, A. Development of selective alpha 7 NNR agonists for the treatment of schizophrenia. Abstracts of Papers, 236th ACS National Meeting, Philadelphia, PA, United States, August 17-21, 2008, MEDI-222.
60. Myers, J. K.; Bodnar, A. L.; Cortes-Burgos, L. A.; Dinh, D. M.; Groppi, V. E.; Hajos, M.; Higdon, N. R.; Hoffmann, W. E.; Hurst, R. S.; Wall, T. M.; Wolfe, M. L.; Wong, E. Synthesis and activity of a potent and selective alpha 7 nAChR agonist: PNU-282987. Abstracts of Papers, 225th ACS National Meeting, New Orleans, LA, United States, March 23-27, 2003, MEDI-224.
61. Wishka, D. G. Design, synthesis, and SAR of azabicyclic aryl amides as a7 nicotinic acetylcholine receptor agonists for the treatment of cognitive deficits in schizophrenia and Alzheimer's disease: Discovery of PHA-543,613. Abstracts of Papers, 234th ACS National Meeting, Boston, MA, United States, August 19-23, 2007, MEDI-258.
62. Haydar, S. N.; Ghiron, C.; Bettinetti, L.; Bothmann, H.; Comery, T. A.; Dunlop, J.; La Rosa, S.; Micco, I.; Pollastrini, M.; Quinn, J.; Roncarati, R.; Scali, C.; Valacchi, M.; Varrone, M.; Zanaletti, R., SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist. Bioorg. Med. Chem., 2009, 17, 5247-5258.
63. Feuerbach, D.; Lingenhoehl, K.; Olpe, H.-R.; Vassout, A.; Gentsch, C.; Chaperon, F.; Nozulak, J.; Enz, A.; Bilbe, G.; McAllister, K.; Hoyer, D. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology, 2009, 56, 254-263.
64. Mueller, W.; Nozulak, J.; Roy, B. L. Preparation of substituted pyrrolidine-2-ones as alpha 7 nicotinic acetylcholine receptor agonists. EP2005118535, 2005.
65. Elworthy, T. R.; Du Bois, D. J.; Tracy, J. L.; Sahdeo, S.; Maag, H., Salicylamides as positive allosteric modulators of nAChR-alpha7. Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, United States, March 22-26, 2009, MEDI-039.
66. Tatsumi, R.; Fujio, M.; Takanashi, S.-i.; Numata, A.; Katayama, J.; Satoh, H.; Shiigi, Y.; Maeda, J.-i.; Kuriyama, M.; Horikawa, T.; Murozono, T.; Hashimoto, K.; Tanaka, H. (R)-3′-(3-methylbenzo [b]thiophen-5-yl)spiro[1- azabicyclo[2,2,2]octane-3,5′-oxazolidin]-2′-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties. J. Med. Chem., 2006, 49, 4374-4383.
67. Ji, J.; Li, T.; Sippy, K. B.; Lee, C.-H.; Gopalakrishnan, M. Preparation of biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators. US2009067579, 2009.
68. Ng, H. J.; Whittemore, E. R.; Tran, M. B.; Hogenkamp, D. J.; Broide, R. S.; Johnstone, T. B.; Zheng, L.; Stevens, K. E.; Gee, K. W. Nootropic alpha 7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc. Natl. Acad. Sci. USA, 2007, 104, 8059-8064.
69. Shumsky, J. S.; Kao, T.; Amato, N.; Simansky, K.; Murray, M.; Moxon, K. A., Partial 5-HT1A receptor agonist activity by the 5-HT2C receptor antagonist SB 206,553 is revealed in rats spinalized as neonates. Exp. Neurol., 2005, 191, 361-365.
70. Faghih, R.; Gopalakrishnan Sujatha, M.; Gronlien Jens, H.; Malysz, J.; Briggs Clark, A.; Wetterstrand, C.; Ween, H.; Curtis Michael, P.; Sarris Kathy, A.; Gfesser Gregory, A.; El-Kouhen, R.; Robb Holly, M.; Radek Richard, J.; Marsh Kennan, C.; Bunnelle William, H.; Gopalakrishnan, M. Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor. J. Med. Chem., 2009, 52, 3377-3384.
71. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Anderson, D. J.; Gopalakrishnan, M.; Xue, I. C.; Piattoni-Kaplan, M.; Molinari, E.; Campbell, J. E.; McKenna, D. G.; Gunn, D. E.; Lin, N.-H.; Ryther, K. B.; He, Y.; Holladay, M. W.; Wonnacott, S.; Williams, M.; Arneric, S. P. ABT-089 [2-methyl-3-(2-(S)- pyrrolidinylmethoxy) pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J. Pharmacol. Exp. Ther., 1997, 283, 235-246.
72. Prendergast, M. A.; Jackson, W. J.; Terry, A. V., Jr.; Decker, M. W.; Arneric, S. P.; Buccafusco, J. J. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology (Berlin), 1998, 136, 50-58.